Germany is moving ahead with an ambitious effort to reduce a widening shortfall in its public health-insurance system, unveiling reforms designed to curb spending across pharmaceuticals and hospitals. The ruling coalition led by Chancellor Friedrich Merz says the measures are aimed at closing a gap forecast to reach €40 billion by 2030.
Chancellor Merz has called the legislative package "historic." Lawmakers say the changes are intended to rein in a system that currently consumes more than half a trillion euros each year.
At the center of the reforms are tougher rules on drug pricing and additional limits on medicine spending. Under the proposed framework, pharmaceutical companies would be required to provide larger rebates to insurers. Those rebates are slated to rise to roughly 10.5% beginning in 2027.
Insurers would also gain expanded authority to group similar patented medicines together for reimbursement purposes, a mechanism designed to encourage prescriptions of lower-cost alternatives within therapeutic categories.
The pharmaceutical lobby has sounded alarm about the potential consequences. Han Steutel, president of the German pharma association VFA, told reporters the measures will have the "worst impact we’ve seen so far," warning that jobs could shift abroad and that patients might receive "the cheapest, rather than the best" medicines.
Industry concerns about Europe's competitiveness are intensifying at a moment when the sector is also facing international pressure. The package comes as the U.S. considers policy changes aimed at bringing domestic drug prices closer to lower international rates, adding another source of uncertainty for European firms.
Some companies are already reacting to the changing environment. Insmed Inc. recently decided not to launch a new lung treatment in Germany, citing the evolving policy landscape. Paola Casarosa, a board member at Boehringer Ingelheim GmbH, said it is becoming "increasingly difficult to launch innovation in Europe" and expressed concern that an ageing population could lose access to the newest medical breakthroughs.
The reforms extend beyond pharmaceuticals. Officials are targeting hospitals, which are identified as the main contributor to rising health-care costs. Proposed steps include requiring second opinions for frequently performed operations and limiting the scope of reimbursements tied to escalating staff costs.
The market reaction has been immediate in some corners. Shares of private hospital operator Fresenius SE have declined by roughly 20% since February. Chief Executive Officer Michael Sen criticized how the plan was executed, describing it as a "missed opportunity" to fundamentally redesign what he called a "chronically inefficient" system.
Key points
- Germany's coalition has proposed reforms to close an expected €40 billion deficit in public health-insurance funds by 2030.
- Drugmakers will face higher mandated rebates, rising to about 10.5% from 2027, and insurers can group similar patented medicines to push lower-cost alternatives.
- Hospitals are targeted with measures such as mandatory second opinions for common procedures and limits on reimbursements for rising staff costs; market impacts already include a roughly 20% drop in Fresenius SE shares since February.
Risks and uncertainties
- Pharmaceutical competitiveness in Europe may weaken if firms shift jobs abroad or limit product launches in Germany, affecting innovation access for patients.
- Hospital operators face revenue and margin pressure from tighter reimbursements and procedural controls, as signaled by recent share-price declines.
- Policy developments in the U.S. that seek to align domestic drug prices with lower international rates could compound pressures on European drugmakers.